AgingResearch.NewsJoin free

MDD US Operations

Part of Supernus Pharmaceuticals

CompanyUnited States

MDD US Operations develops one asset, approved (APOKYN). Mostly small molecule acting on DRD2, DRD4 and DRD3; based in the United States.

1
Asset
Furthest stage
Approved
3
Trials
0
Signals

Pipeline

1

  • APOKYN

    Dopamine receptor agonist that stimulates dopamine receptors to treat motor fluctuations in Parkinson's disease

    Approved, Small molecule, DRD2, DRD4, motor symptoms (Phase 3), Parkinson's disease (Phase 3)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials3
  • Similar companies6

Intelligence